Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
| 대상 질환 | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | University of California, San Diego |
| 상태 | 완료 |
| 참여자 수 | 7 명 |
| 중재(약물) | Pembrolizumab, Tadalafil |
| 시작일 | 2020년 4월 7일 |
| 완료일 | 2022년 4월 16일 |
| 결과 공개일 | 2026년 2월 12일 |
요약
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Rate of Dose Limiting Toxicity (DLT)
| Tadalafil and Pembrolizumab | 1 Participants |
|---|
Overall Survival (OS)
| Tadalafil and Pembrolizumab | 3 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner